Antioxidant activity and sex differences of acute vascular effects of amiodarone in advanced atherosclerosis

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 5, 2007, Pages 578-584

  Traupe, Tobias ^a   Keller, Mario ^a   Fojtu, Eva ^a   Bhattacharya, Indranil ^a   Lang, Matthias ^a   Ha, Huy Riem ^a   Jochum, Wolfram ^b   Mundy, Alexa L ^a   Barton, Matthias ^a,b  

^a UNIVERSITÄTSSPITAL ZÜRICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Arrhythmia; Coronary artery disease; Hypercholesterolemia; Ischemia; Therapy

Indexed keywords

AMIODARONE; SUPEROXIDE; XANTHINE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTERY ENDOTHELIUM; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG UPTAKE; FEMALE; HEART ARRHYTHMIA; HEART MUSCLE RELAXATION; HEART RHYTHM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEX DIFFERENCE; VASCULAR TISSUE; VASODILATATION;

ACETYLCHOLINE; AMIODARONE; ANIMALS; ANTIOXIDANTS; AORTA; APOLIPOPROTEINS E; CORONARY ARTERY DISEASE; FEMALE; MALE; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; NITROPRUSSIDE; PHENYLEPHRINE; SEX FACTORS; SUPEROXIDES; VASOCONSTRICTION; VASODILATION; VASODILATOR AGENTS; XANTHINE; XANTHINE OXIDASE;

EID: 36348979875     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31814d6674     Document Type: Article

References (49)

1. Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;4:499-503.
2. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;23:1801-1811.
3. Sugioka K, Shimosegawa Y, Nakano M. Estrogens as natural antioxidants of membrane phospholipid peroxidation. FEBS Lett. 1987;1:37-39.
4. Cheng J. Evidences of the sex-related differences in cardiac repolarization and the underlying mechanisms in different animal species and human. Fundam Clin Pharmacol. 2006;1:1-8.
5. Charlier R, Delaunois G, Bauthier J, et al. [Research on the benzofuran series. XL. Anti-arrhythmic properties of amiodarone]. Cardiologia. 1969;2:83-90.
6. Singh BN. Amiodarone: historical development and pharmacologic profile. Am Heart J. 1983;4 Pt 2:788-797.
7. Gonzalez ER, Kannewurf BS, Ornato JP. Intravenous amiodarone for ventricular arrhythmias: overview and clinical use. Resuscitation. 1998;1-2:33-42.
8. Kodama I, Kamiya K, Toyama J. Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol. 1999;9A:20R-28R.
9. Charlier R, Tondeur R, Deltour G, et al. Recherches dans la serie des benzofurannes. VII. Etude pharmacologique preliminaire du butyl-2(diiodo- 3′,5′ beta-N-diethylaminoethoxy-4′ benzoyl)-3 benzofuranne. Arch Int Pharmacod T. 1962;1-2:255-264.
10. Lapenna D, Ciofani G, Bruno C, et al. Antioxidant activity of amiodarone on human lipoprotein oxidation. Br J Pharmacol. 2001;5:739-745.
11. Ide T, Tsutsui H, Kinugawa S, et al. Amiodarone protects cardiac myocytes against oxidative injury by its free radical scavenging action. Circulation. 1999;7:690-692.
12. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol. 2003;2:R277-R297.
13. Goette A, Lendeckel U. Nonchannel drug targets in atrial fibrillation. Pharmacol Ther. 2004;1:17-36.
14. Hool LC. What cardiologists should know about calcium ion channels and their regulation by reactive oxygen species. Heart Lung Circ. 2007 Mar 10;[Epub ahead of print].
15. Akar FG, Aon MA, Tomaselli GF, et al. The mitochondrial origin of postischemic arrhythmias. J Clin Invest. 2005;12:3527-3235.
16. Barton M, Haudenschild CC, d'Uscio LV, et al. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA. 1998;24:14367-14372.
17. Ha HR, Bigler L, Wendt B, et al. Identification and quantitation of novel metabolites of amiodarone in plasma of treated patients. Eur J Pharm Sci. 2005;4:271-279.
18. Brien JF, Jimmo S, Brennan FJ, et al. Distribution of amiodarone and its metabolite, desethylamiodarone, in human tissues. Can J Physiol Pharmacol. 1987;3:360-364.
19. Candinas R, Frielingsdorf J, Ha HR, et al. Myocardial amiodarone concentrations after short- and long-term treatment in patients with end-stage heart failure. Eur J Clin Pharmacol. 1998;5:331-336.
20. Ha HR, Stieger B, Grassi G, et al. Structure-effect relationships of amiodarone analogues on the inhibition of thyroxine deiodination. Eur J Clin Pharmacol. 2000;11-12:807-814.
21. Daiber A, August M, Baldus S, et al. Measurement of NAD(P)H oxidasederived superoxide with the luminol analogue L-012. Free Radic Biol Med. 2004;1:101-11.
22. Traupe T, Lang M, Goettsch W, et al. Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens. 2002;11:2239-2245.
23. Waelti ER, Barton M. Rapid endocytosis of copper-zinc superoxide dismutase into human endothelial cells: role for its vascular activity. Pharmacology. 2006;4:198-201.
24. Cote P, Bourassa MG, Delaye J, et al. Effects of amiodarone on cardiac and coronary hemodynamics and on myocardial metabolism in patients with coronary artery disease. Circulation. 1979;6:1165-1172.
25. Kosinski EJ, Albin JB, Young E, et al. Hemodynamic effects of intravenous amiodarone. J Am Coll Cardiol. 1984;3:565-570.
26. Munoz A, Karila P, Gallay P, et al. A randomized hemodynamic comparison of intravenous amiodarone with and without Tween 80. Eur Heart J. 1988;2:142-148.
27. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med. 1999;12:871-878.
28. Rodrigues AJ, Evora PR, Maruo A, et al. [Amiodarone causes endothelium-dependent vasodilation in canine coronary arteries.] Arq Bras Cardiol. 2005;3:251-255.
29. Guiraudou P, Pucheu SC, Gayraud R, et al. Involvement of nitric oxide in amiodarone- and dronedarone-induced coronary vasodilation in guinea pig heart. Eur J Pharmacol. 2004;1-3:119-127.
30. Gessner G, Heller R, Hoshi T, et al. The amiodarone derivative 2-methyl-3-(3,5-diiodo-4-carboxymethoxybenzyl)benzofuran (KB130015) opens large-conductance Ca(2+)-activated K(+) channels and relaxes vascular smooth muscle. Eur J Pharmacol. 2007;555:185-193.
31. Plomp TA, Wiersinga WM, van Rossum JM, et al. Pharmacokinetics and body distribution of amiodarone and desethylamiodarone in rats after intravenous administration. In Vivo. 1989;1:33-47.
32. Bellen JC, Penglis S, Tsopelas C. Radiolabeling and biodistribution of amiodarone and desethylamiodarone. Nucl Med Biol. 1995;7:953-955.
33. Plomp TA, van Rossum JM, Robles de Medina EO, et al. Pharmacokinetics and body distribution of amiodarone in man. Arzneimittelforschung. 1984;4:513-520.
34. Roden DM. Mechanisms underlying variability in response to drug therapy: implications for amiodarone use. Am J Cardiol. 1999;9A:29R-36R.
35. Ross G, Stinson E, Schroeder J, et al. Spontaneous phasic activity of isolated human coronary arteries. Cardiovasc Res. 1980;10:613-618.
36. Dagassan PH, Clozel M, Breu V, et al. Role of endothelin in spontaneous phasic contraction of human coronary arteries. J Cardiovasc Pharmacol. 1995;S200-S203.
37. Sun H, Mohri M, Shimokawa H, et al. Coronary microvascular spasm causes myocardial ischemia in patients with vasospastic angina. J Am Coll Cardiol. 2002;5:847-851.
38. Kugiyama K, Yasue H, Okumura K, et al. Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation. 1996;3:266-271.
39. Cox ID, Botker HE, Bagger JP, et al. Elevated endothelin concentrations are associated with reduced coronary vasomotor responses in patients with chest pain and normal coronary arteriograms. J Am Coll Cardiol. 1999;2:455-460.
40. Motoyama T, Kawano H, Kugiyama K, et al. Vitamin E administration improves impairment of endothelium-dependent vasodilation in patients with coronary spastic angina. J Am Coll Cardiol. 1998;6:1672-1679.
41. Nattel S, Talajic M, Quantz M, et al. Frequency-dependent effects of amiodarone on atrioventricular nodal function and slow-channel action potentials: evidence for calcium channel-blocking activity. Circulation. 1987;2:442-449.
42. Traupe T, Lang M, Ortmann J, et al. Amiodarone acutely inhibits vascular activity of endothelin-converting enzymes. J Cardiovasc Pharmacol. 2004;44:S113-S116.
43. Kawano H, Motoyama T, Ohgushi M, et al. Menstrual cyclic variation of myocardial ischemia in premenopausal women with variant angina. Ann Intern Med. 2001;11:977-981.
44. Kawano H, Motoyama T, Hirai N, et al. Estradiol supplementation suppresses hyperventilation-induced attacks in postmenopausal women with variant angina. J Am Coll Cardiol. 2001;3:735-740.
45. Rienstra M, Van Veldhuisen DJ, Hagens VE, et al. Sex-related differences in rhythm control treatment in persistent atrial fibrillation: data of the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol. 2005;7:1298-1306.
46. Wysocka E, Wysocki H, Siminiak T, et al. Effect of selected anti-arrhythmic drugs on the superoxide anion production by polymorphonuclear neutrophils in vitro. Cardiology. 1989;4:264-269.
47. Kim YM, Guzik TJ, Zhang YH, et al. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res. 2005;7:629-636.
48. Himmel HM, Dobrev D, Grossmann M, et al. N-desethylamiodarone modulates intracellular calcium concentration in endothelial cells. Naunyn Schmiedebergs Arch Pharmacol. 2000;6:489-496.
49. Chen Z, Yuhanna IS, Galcheva-Gargova Z, et al. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest. 1999;3:401-406.